secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bionano Genomics, Inc. (BNGO)
CIK:        0001411690
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001411690-24-000020
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bionano Q1 revenue $8.8M (+18% YoY); cash burn down 41% YoY; restructuring charges $4.6M
--------------------------------------------------------------------------------

- Q1 2024 revenue $8.8M, +18% YoY; GAAP gross margin 32% vs 28% in Q1 2023.
- Operating cash burn (excl. interest/debt) $19M in Q1 2024, down from $32M in Q1 2023.
- Reaffirmed FY2024 revenue guidance of $37-41M; Q2 2024 revenue expected $7.8-8.2M.
- Installed base of 347 OGM systems (+34% YoY); flowcell sales up 58% to 8,249 units.
- Restructuring charges of ~$4.6M from March 2024 RIF; substantially complete by June 30, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411690/000141169024000020/0001411690-24-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411690/000141169024000020/bngo-20240508.htm
  HTML page:      https://secwatch.observer/filing/0001411690-24-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer